Lymphoma Clinical Trials in Ohio

Showing 321-340 of 609 trials

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

NCT02395601

First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.

B-Cell Lymphoma

Constellation Pharmaceuticals41 participantsStarted Mar 2015

Lafayette, Indiana, United States • Boston, Massachusetts, United States • Omaha, Nebraska, United States +3 more locations

COMPLETEDPhase 232 miles

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

NCT02639910

This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as part of combination therapy. Patients completing the study treatment are invited to participate in an optional biomarker sub-study.

Leukemia, Lymphocytic, Chronic, B-CellChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

MorphoSys AG24 participantsStarted Nov 2016

Jacksonville, Florida, United States • Rochester, Minnesota, United States • Columbus, Ohio, United States +14 more locations

PreviousPage 17 of 31Next

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi

Lymphoma Trials in Other Cities

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Double Cord Versus Haploidentical (BMT CTN 1101)

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

A Study of LY3023414 in Participants With Advanced Cancer

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Other Conditions in Ohio